Top Market Shifts Transforming the Shingles Vaccine Market Landscape: Key Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Shingles Vaccine Market Through 2025?
The market for the shingles vaccine has experienced swift growth in past years. Projections show that it will increase from $4.82 billion in 2024 to $5.55 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 15.0%. This surge during the historic period is a result of factors such as a growing older population, heightened awareness about the advantages of vaccines, expanding healthcare infrastructure and immunization schemes, increasing occurrence of conditions that compromise the immune system, and rising uptake of more recent, high-efficacy vaccines.

What's the Projected Size of the Global Shingles Vaccine Market by 2029?
Expectations are high for the shingles vaccine market size to experience significant expansion in the coming years, with a projected rise to $9.58 billion in 2029 and a 14.6% compound annual growth rate (CAGR). Various factors are contributing to this anticipated growth during the forecast period; including the increase in government reimbursement and appealing pricing strategies, a rise in the rate of physician referrals, the heightened focus on adult immunization in public health agendas, considerable investment in product diversification and R&D, and enhancements in the global supply chain and cold-chain capacity. Looking forward, the forecast period is expected to see the evolution of recombinant vaccine technology, progression in adjuvant systems, the inclusion of shingles vaccinations in adult immunization timetables, the integration of digital health technology for tracking vaccines, and advancements in vaccine formulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

Top Growth Drivers in the Shingles Vaccine Industry: What's Accelerating the Market?
The growth trajectory of the shingles vaccine market is projected to be positively influenced by the rising number of vaccination schemes. The term 'vaccination schemes' primarily indicates publicly organized health interventions that involve systematic vaccine administration to communities for inhibiting the transmission of contagious diseases. The proliferation of these schemes is resulting from growing awareness regarding the benefits of preventive healthcare, subsequently inspiring more individuals to opt for vaccination to preempt illnesses. By fostering public awareness and accessibility, vaccination programs help enlarge the user base of the shingles vaccine, rendering them particularly beneficial for seniors and vulnerable groups. These programs aid in reducing shingles and associated complications incidence by advocating for timely and extensive immunization, thereby improving overall public health. For example, as reported by the World Health Organization in July 2025, a Switzerland-based Intergovernmental entity, the reach for the primary dose of the human papillomavirus (HPV) vaccine in females witnessed a surge from 27% in 2023 to 31% in 2024. Thus, the escalating number of vaccination schemes is a key growth driver for the shingles vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

Which Emerging Trends Are Transforming the Shingles Vaccine Market in 2025?
Leading corporations in the shingles vaccine market are concentrating on the creation of innovative vaccine compounds, such as recombinant adjuvanted vaccines, to strengthen immune response and offer continuous protection from shingles. By combining lab-created viral proteins with adjuvants, recombinant adjuvanted vaccines can enhance the body's immune resilience for greater and longer-lasting protection. For example, GlaxoSmithKline Pharmaceuticals Ltd., an pharmaceutical firm based in India, introduced a shingles vaccine called Shingrix in April 2023. Aimed at adults aged 50 and over, Shingrix is a non-live, recombinant adjuvanted subunit vaccine given in two intramuscular doses to prevent shingles (herpes zoster) and its subsequent issue, post-herpetic neuralgia. This vaccine, with an effectiveness rate of over 90%, offers strong and long-lasting immunity for at least 10 years, benefiting even older adults and those with compromised immune systems.

What Are the Main Segments in the Shingles Vaccine Market?
The shingles vaccine market covered in this report is segmented

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine
2) By Product: Shingrix, Zostavax, Skyzoster
3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above
4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:
1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C
2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine
3) By Subunit Vaccine: Protein Subunit Vaccine, Polysaccharide Subunit Vaccine, Conjugate Subunit Vaccine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27413&type=smp

Which Top Companies are Driving Growth in the Shingles Vaccine Market?
Major companies operating in the shingles vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GSK plc, Daiichi Sankyo Company Limited, Moderna Inc., Novavax Inc., Biological E. Limited., Serum Institute of India Pvt. Ltd., Dynavax Technologies Corporation, SK Bioscience Co. Ltd., CanSino Biologics Inc., Vaxart Inc., EuBiologics Co. Ltd., BCHT Biotech Co. Ltd., Green Cross Corp, Jiangsu Recbio Technology Co. Ltd., Curevo Inc., Inovio Pharmaceuticals Inc., POP Biotechnologies Inc.

Which Regions Will Dominate the Shingles Vaccine Market Through 2029?
North America was the largest region in the shingles vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27413

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.